Corcept (CORT) trading halted, news pending; Bloomberg reporting the company has won FDA approval for its Korlym in Cushing's syndrome
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Join SI Premium – FREE
Corcept (Nasdaq: CORT) trading halted with news pending. Bloomberg reporting the company has won FDA approval for its Korlym in Cushing's syndrome.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
- Keenova doses first patient in Phase 3 hammer toe drug trial
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Rumors, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
